ACADIA PHARMACEUTICALS INC — Director's Dealing 2014

Feb 28, 2014

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ACADIA PHARMACEUTICALS INC (ACAD)
CIK: 0001070494
Period of Report: 2014-02-26

Reporting Person: Baity Glenn (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2014-02-26	Common Stock	M	42000	$6.17	Acquired	89788	Direct
2014-02-26	Common Stock	S	42000	$30.279	Disposed	47788	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2014-02-26	Stock Option (right to buy)	$6.17	M	42000	Disposed	2014-07-25	Common Stock (42000)	Direct

Footnotes

F1: Includes 2,273 and 5,515 shares acquired on May 31, 2013 and November 29, 2013, respectively, by Mr. Baity under the ACADIA Pharmaceuticals Employee Stock Purchase Plan.

F2: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in September 2013.

F3: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.62 per share, inclusive. The reporting person undertakes to provide ACADIA Pharmaceuticals Inc., any security holder of ACADIA Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the foregoing range.

F4: 25% of the shares subject to the stock option vested and became exercisable on July 26, 2005. The remaining shares vested in equal monthly installments over the following 3 years.